FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Merck, Eisai discontinue late-stage study for liver cancer therapy
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
Europe to review safety data for Eisai-Biogen Alzheimer's drug
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug
Japan's Eisai developing dementia drug for US market, Nikkei reports
Eisai and Biogen launch Alzheimer's drug Leqembi in China